Insmed Incorporated (INSM)
NASDAQ: INSM · IEX Real-Time Price · USD
74.54
+0.04 (0.05%)
At close: Jul 26, 2024, 4:00 PM
75.75
+1.21 (1.62%)
After-hours: Jul 26, 2024, 7:28 PM EDT
Insmed Revenue
Insmed had revenue of $75.50M in the quarter ending March 31, 2024, with 15.77% growth. This brings the company's revenue in the last twelve months to $315.49M, up 22.54% year-over-year. In the year 2023, Insmed had annual revenue of $305.21M with 24.39% growth.
Revenue (ttm)
$315.49M
Revenue Growth
+22.54%
P/S Ratio
38.09
Revenue / Employee
$345,936
Employees
912
Market Cap
12.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
Dec 31, 2019 | 136.47M | 126.63M | 1,287.56% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fresenius Medical Care AG & Co. KGaA | 21.17B |
Universal Health Services | 14.66B |
DaVita | 12.34B |
Smith & Nephew | 5.55B |
Charles River Laboratories International | 4.11B |
Royalty Pharma | 2.24B |
Medpace Holdings | 2.03B |
Natera | 1.21B |
INSM News
- 21 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 23 days ago - Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference - PRNewsWire
- 4 weeks ago - Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 - PRNewsWire
- 6 weeks ago - Top 4 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 7 weeks ago - Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference - PRNewsWire
- 2 months ago - Insmed to Host Commercial Webinar on June 4, 2024 - PRNewsWire
- 2 months ago - Insmed Announces Pricing of $650 Million Public Offering of Common Stock - PRNewsWire
- 2 months ago - Insmed Announces Proposed $500 Million Public Offering of Common Stock - PRNewsWire